Novartis Pharmaceuticals Canada Inc. is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio® ...

Company N.V. announced that the European Medicines Agency, EMA, has validated the Marketing Authorization Application, ...

Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia ...

To determine whether human X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome (IPEX; MIM 304930) is the genetic equivalent of the scurfy (sf) mouse, we sequenced the ...

The experimental cholesterol drug obicetrapib slowed Alzheimer’s biomarkers, over 12 months in patients with cardiovascular ...

Learn more about paternal zygosity testing, which can help reveal if there is a risk of a fetus developing HDFN.

Objective Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is an inherited adrenal steroid synthesis disorder included in Dutch newborn screening (NBS) since 2002. Screening ...

Homozygous deficiency of alpha1-atitrypsin is known to predispose to pulmonary emphysema. Measurement of the trypsin inhibitory capacity (TIC) of serum specimens from 28 relatives of a homozygous p ...

A study has identified a key disruption in cholesterol transport to the brain in patients with Alzheimer's disease. The findings suggest that the lipoproteins in the cerebrospinal fluid of ...

The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.